McKesson back on track to secure acquisition of Celesio
US health care services and information technology firm McKesson Corp (NYSE:MCK), says that it has reached an agreement with Franz Haniel & Cie to acquire its entire holding (50%) of German drug wholesaler Celesio (CLS1: XE) shares for 23.50 euros per share, still its previous final offer for the company.
Just earlier this month, McKesson appeared to have abandoned its $8.3 billion deal to acquire its German rival after it was unsuccessful in reaching the 75% completion condition in its offer for the outstanding shares and convertible bonds of Celesio (The Pharma Letter January 14).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze